1427-TIGIT Blockade Enhances BCMA-CAR-T Efficacy in Myeloma

This research article examines the role of the TIGIT immune checkpoint in driving resistance and relapse following BCMA-CAR-T therapy in patients with multiple myeloma. By utilizing single-cell RNA sequencing and flow cytometry, the authors demonstrate that high TIGIT expression on T cells correlates with increased tumor burden, poor prognosis, and accelerated T cell exhaustion. While in vitro inhibition showed limited results, TIGIT blockade using monoclonal antibodies in humanized mouse models significantly enhanced CAR-T proliferation and antitumor efficacy. Transcriptomic analysis further suggests that TIGIT modulates these effects by regulating cytokine pathways and the transcription factor BATF3. Ultimately, the study identifies TIGIT as a critical therapeutic target to overcome treatment resistance and improve the durability of CAR-T responses in myeloma patients.References:Xia Y, Zhu J, Guo R, et al. Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy[J]. Cell death & disease, 2025, 16(1): 890.前往小宇宙评论区与主播互动